There is no evidence for an association between cerebral β-amyloid deposition, a marker of Alzheimer disease, and intracranial atherosclerotic plaque or stenosis.
The FDA has granted Orphan Drug designation to RT001 (Retrotope) for the treatment of progressive supranuclear palsy (PSP).
Higher flavonol intake through food sources, mostly fruits and vegetables, may protect against the development of Alzheimer disease.
Compared with standard care alone, outpatient palliative care is associated with benefits among patients with Parkinson disease and related disorders.
Topline data were announced from the phase 2/3 DIAN-TU study of solanezumab (Eli Lilly) and gantenerumab (Genentech) in patients at risk for or with dominantly inherited Alzheimer disease.
Compared with their peers, Asian patients with dementia were less likely to be prescribed antidementia drugs, and they received these drugs for fewer days per year.
Risdiplam is an investigational, orally administered liquid survival motor neuron-2 (SMN2) splicing modifier designed to increase and sustain SMN protein levels throughout the central nervous system and peripheral tissues of the body.
Higher gamma-glutamyltransferase variability was found to be significantly associated with increased risk for dementia among patients with diabetes.
The Food and Drug Administration (FDA) has approved updates to the prescribing information for Belsomra® (suvorexant; Merck) to include study findings for the treatment of insomnia in patients with mild to moderate Alzheimer disease.
Road proximity is associated with an increased incidence of specific neurologic disorders.